

HPV Primary Screening Literature Update 2021

Rationale for HPV primary screening

1. Dillner J et al 2008. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. *BMJ* 2008;377:a1754 doi:10.1136/bmj.a1754
2. Ronco G, et al. 2013. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. *The Lancet Volume* 383, No. 9916, p524–532.
3. Kitchener, HC et al. 2011. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. *European Journal of Cancer* 47(6): 864–71.
4. Katki et al. 2011. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. *The Lancet Oncology Volume* 12, Issue 7, 663–672.
5. Elfstrom KM et al. 2014. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. *British Medical Journal* 348: g130.
6. Wright TC et al. 2015. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test *Gynecol Oncol.* 2015 Feb;136(2):189-97. doi: 10.1016/j.ygyno.2014.11.076. Epub 2015 Jan 8.

Screening Strategies and effectiveness

7. Lew J-B et al. 2016. Effectiveness Modelling and Economic Evaluation of Primary HPV Screening for Cervical Cancer Prevention in New Zealand *PLOS ONE* | DOI:10.1371/journal.pone.0151619 May 17, 2016
8. Hall MT et al 2019. The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications. *Gynecologic Oncology* 152 (2019) 472–479
9. Machalek DA et al 2019. Routine cervical screening by primary HPV testing: early findings in the renewed National Cervical Screening Program. *MJA* 211 (3) ▪ 5 August 2019
10. Huh WK et al 2015. Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance. *Gynecol Oncol* (2015), <http://dx.doi.org/10.1016/j.ygyno.2014.12.022>
11. Castle et al. 2011. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. *The Lancet Oncology*: 12:9. 880–890.
12. Cancer Council Australia Clinical Guidelines Network re Oncogenic HPV types not 16/18 available at: https://wiki.cancer.org.au/australia/Clinical_question:Oncogenic HPV types not 16/18
13. WHO Global strategy to accelerate the elimination of cervical cancer as a public health problem 2020. Available at <https://www.who.int/publications/i/item/9789240014107>
14. Polman NJ et al. 2019. Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial. *Lancet Oncol*: Published Online January 15, Available at: [http://dx.doi.org/10.1016/S1470-2045\(18\)30934-3](http://dx.doi.org/10.1016/S1470-2045(18)30934-3)

15. Gori S et al 2020. Clinical relevance of partial HPV16/18 genotyping in stratifying HPV-positive women attending routine cervical cancer screening: a population-based cohort study. *BJOG*: 128:8. 1353-1362.
16. Song F et al. 2021. Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16^{INK4a} immunostaining in China. *BMC Infectious Diseases*: 21:400. Available at: <https://doi.org/10.1186/s12879-021-06109-4>
17. Wright TC et al. 2017. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial. *Gynecologic Oncology*: 144:1. 51-56. Available at: [10.1016/j.ygyno.2016.10.031](https://doi.org/10.1016/j.ygyno.2016.10.031)
18. Machalek DA et al. 2019. Routine cervical screening by primary HPV testing: early findings in the renewed National Cervical Screening Program. *The Medical Journal of Australia*: 211:3. 113-119.
19. Demarco M et al. 2020. A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. *The Lancet*: 22 (2020) 100293. Available at: <https://doi.org/10.1016/j.eclinm.2020.100293>
20. Kaljouw S et al. 2021. Reducing unnecessary referrals for colposcopy in hrHPV-positive women within the Dutch cervical cancer screening programme: A modelling study. *Gynecologic Oncology*: 160:3. 713-720.
21. National Cervical Screening Program (NCSP). [National Cancer Screening Register \(NCSR\) Unpublished data](#). Department of Health, Australian Commonwealth Government; 2020 Apr 16. Report No.: [Search period: 1 December 2017 to 31 December 2019].

Equity and screening special groups

22. Smith MA 2017. Impact of the National Cervical Screening Programme in New Zealand by age: analysis of cervical cancer trends 1985–2013 in all women and in Māori women. *Cancer Causes Control* (2017) 28:1393–1404 DOI 10.1007/s10552-017-0967-y
23. Teng et al 2016. Ethnic inequalities in cancer incidence and mortality: census-linked cohort studies with 87 million years of person-time follow-up. *BMC Cancer* (2016) 16:755 DOI 10.1186/s12885-016-2781-4
24. MacDonald EJ 2020. Reaching under-screened/never-screened indigenous peoples with human papilloma virus self-testing: A community-based cluster randomised controlled trial. *Aust N Z J Obstet Gynaecol* 2020; 1–7 DOI: 10.1111/ajo.13285

Self-Testing (self-sampling)

25. Arbyn M et al 2018. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. *BMJ* 2018;363:k4823 <http://dx.doi.org/10.1136/bmj.k4823>
26. Madzima TR 2017. Emerging role of HPV self-sampling in cervical cancer screening for hard-to-reach women Focused literature review. *Can Fam Physician* 2017;63:597-601
27. Adcock et al. 2019. Acceptability of self- taken vaginal HPV sample for cervical screening among an under-screened Indigenous population *Aust N Z J Obstet Gynaecol* 2019; 59: 301–307 DOI: 10.1111/ajo.12933
28. Hawkes D. et al 2020. Self-Collection for Cervical Screening Programs: From Research to Reality. *Cancers* 2020, 12, 1053; doi:10.3390/cancers12041053
29. Smith M et al 2016. Impact of HPV sample self-collection for underscreened women in the renewed Cervical Screening Program *MJA* 204 (5) j 21 March 2016 doi: 10.5694/mja15.00912

HPV Immunisation Impact

30. Palmer et al 2019. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study *BMJ* 2019;365:l1161 <http://dx.doi.org/10.1136/bmj.l1161>
31. Garland SM 2016. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience *Clin Infect Dis* 2016;63(4):519-27
32. Moreira ED et al 2016. Safety profile of the 9-valent HPV vaccine: a combined analysis of 7 phase III clinical trials. *Pediatrics* 2016;138(2):e20154387
33. Innes CRH et al 2020. Impact of human papillomavirus vaccination on rates of abnormal cervical cytology and histology in young New Zealand women *NZMJ* 17 January 2020, Vol 133 No 1508
34. Tabrizi SN et al 2014. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. *Lancet Infect Dis.* 2014 Oct;14(10):958-66. doi: 10.1016/S1473-3099(14)70841-2. Epub 2014 Aug 5.